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RHCE*ceAR encodes a partial c (RH4) antigen
C. Halter Hipsky, C. Lomas-Francis, A. Fuchisawa, and M.E. Reid
The Rh blood group system is highly complex both in the num-
ber of discrete antigens and in the existence of partial antigens, 
especially D and e.  Recently, several partial c antigens have 
been reported. Here we report findings on an African Ameri-
can man with sickle cell disease whose RBCs typed C+c+ and 
whose plasma contained anti-c. Hemagglutination tests, DNA 
extraction, PCR-RFLP, reticulocyte RNA isolation, RT-PCR 
cDNA analyses, cloning, and sequencing were performed by 
standard procedures. RBCs from the patient typed C+c+ but 
his plasma contained alloanti-c. DNA analyses showed the 
presence of RHCE*Ce in trans to RHCE*ceAR with RHD*D 
and RHD*Weak D Type 4.2.2. The amino acid changes on 
RhceAR are such that a C+c+ patient made alloanti-c. This 
case shows that RhceAR carries a partial c antigen and il-
lustrates the value of DNA testing as an adjunct to hemag-
glutination to aid in antibody identification in unusual cases.
Immunohematology 2010;26:57–59.
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The Rh blood group system is the most complex of the 30 human blood group systems.1,2 This is attributable not only to the 50 discrete antigens3 but also to the 
fact that some of the antigens, notably D, C, and e, have nu-
merous altered forms, the so-called partial antigens.4 Par-
tial c antigens have also been described. The fi rst example 
of alloanti-c in a c+ (presumed phenotype R1r) person was 
reported in 1982.5 Anti-Rh26, which can appear as anti-
c, has been made by an Rh26–, c– person6 and also by an 
RH26–, c+ person.7 Molecular studies revealed that Rh26 
is antithetical to the low-prevalence antigen LOCR, and se-
rologic studies have shown that the LOCR+ phenotype en-
codes altered (weakened) expression of c.8 Recently, it has 
been shown that RHCE*ceS(340) and RHCE*(C)ceS each 
encode a partial c antigen.9,10 Each of these alleles encodes a 
different haplotype, and the alloanti-c may not be of identi-
cal specifi city.
 One of a growing number of RHCE*ce alleles that encode 
an Rhce protein with an altered c antigen is RHCE*ceAR. 
RHCE*ceAR has six nucleotide changes (48G>C, 712A>G, 
733C>G, 787A>G, 800T>A, and 916A>G), which predict the 
amino acid changes of Trp16Cys, Met238Val, Leu245Val, 
Arg263Gly, Met267Lys, and Ile306Val, respectively.11 The 
RHCE*ceAR allele encodes an altered e, a weak V, but no 
Rh18 or hrS.12 In this article, we describe serologic and DNA 
testing on blood from a C+c+ African American patient 
whose plasma contains alloanti-c, thereby revealing that 
RHCE*ceAR encodes a partial c antigen. We published this 
fi nding in an abstract,13 and while this manuscript was in 
preparation, a report by Peyrard and coworkers14 appeared 
and thus there are two such cases.
Materials and Methods
 Blood samples from a 17-year-old multi-transfused Af-
rican American man with sickle cell disease were analyzed.
Hemagglutination
 Reagents were from our libraries and obtained from 
numerous colleagues and commercial sources. Hemagglu-
tination was performed in test tubes using the method best 
suited to the antibody being tested. Eluates were prepared 
using Gamma Elu-Kit II (Gamma/Immucor, Norcross, 
GA).
DNA and RNA Isolation, RT-PCR, Sequencing, and 
Cloning
 Genomic DNA was prepared from 200 μL of the buffy 
coat layer of peripheral blood using a DNA extraction kit 
(QIAamp DNA Blood Mini Kit, Qiagen, Valencia, CA). RNA 
was isolated from the reticulocytes (TriZol and PureLink 
Micro-to-Midi Total RNA Purifi cation System, Invitrogen, 
Carlsbad, CA). Reverse transcription was carried out with 
gene-specifi c RHD and RHCE primers listed in Table 1 
and Superscript III, according to manufacturer’s instruc-
tions (Supercript III First Strand Synthesis SuperMix, In-
vitrogen). PCR amplifi cation was carried out with primers 
cRHx1F and cRHx5R to amplify exons 1–4; and cRHx4F and 
cRHx10R to amplify exons 5–10 on RHD (RefSeq accession 
NM_016124) and RHCE (RefSeq accession NM_020485) 
cDNA using HotStarTaq Master Mix Kit (Qiagen). PCR am-
plicons were checked for purity on agarose gels, cleaned 
using ExoSAP-IT (USB Corporation, Cleveland, OH) ac-
cording to manufacturer’s instructions and directly se-
quenced by GeneWiz Inc. (South Plainfi eld, NJ). Cloning 
reactions were carried out and sequenced by GeneWiz Inc. 
Sequences were aligned, and protein sequence comparisons 
were performed using Sequencher v4.8 (GeneCodes, Ann 
Arbor, MI). The complete sequences of RHCE and RHD 
were analyzed using gene-specifi c cDNA direct sequencing, 
and to verify the results and determine which alleles carry 
which alterations, all RT-PCR products of RHCE and RHD 
were also cloned and sequenced. The sequence of RHD 
exon 7 was determined by amplifying and sequencing exon 
7 individually using genomic DNA as described previously. 
To verify the RHCE*ceAR nucleotide change 48G>C that 
does not always sequence well owing to its early position in 
exon 1, PCR-RFLP was conducted on genomic DNA.
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Results
Hemagglutination
 The patient’s RBCs typed as group B, D+C+E–c+e+, 
and his serum contained anti-c. His RBCs were agglutinated 
by 12 commercial anti-c reagents (reagents included mono-
clonal and polyclonal antibodies) to the same strength as 
control RBCs expressing a single dose of c antigen. As this 
was a surprising result given that he had made anti-c, we 
performed DNA analyses.
RH cDNA Sequence Analysis   
 Collectively, the results of DNA analyses showed the 
presence of the following genes: RHD*D, RHD*Weak D 
Type 4.2.2, RHCE*Ce, and RHCE*ceAR. The weak D Type 
4.2.2 allele is the same as the RHD*DAR allele, except it 
harbors a 744C>T and a 957G>A nucleotide change.15 It is 
likely that the two haplotypes in this patient are RHD*D/
RHCE*Ce and RHD*Weak D Type 4.2.2/RHCE*ceAR.
Discussion   
 We report findings on an African American with sickle 
cell disease who had been transfused on numerous occa-
sions. His RBCs typed C+c+, and his serum contained anti-
c reactive by the IAT. This study reveals that the amino acid 
changes on RhceAR (Trp16Cys, Met238Val, Leu245Val, 
Arg263Gly, Met267Lys, and Ile306Val) are such that a 
C+c+ patient can make alloanti-c. Thus, ceAR carries a par-
tial c antigen. The strong reactivity of anti-c reagents with 
the patient’s RBCs that express Ce/ceAR and the absence of 
a known low-prevalence antigen on RBCs expressing ceAR 
preclude detection of the altered c antigen associated with 
ceAR.
 This case shows the value of DNA testing as an adjunct 
to hemagglutination to aid in antibody identification in un-
usual cases. After we published our findings in a prelimi-
nary form13 and while this manuscript was in preparation, 
Peyrard and coworkers reported a case of anti-c in a person 
with the C+/ceAR phenotype.14 Thus, there are two such 
published cases. The clinical relevance of the alloanti-c in 
this latter case is unknown, because after it was identi-
fied, the patient received c– RBC components. Interest-
ingly, to date, the majority of partial c antigens have been in 
persons of African or Hispanic ancestry.
Table 1. Sequence and location of primers
Primer 
name Primer sequence (5′–3′) Location
cDx10R gtattctacagtgcataataaatggtg Exon 10
cCEx10R ctgtctctgaccttgtttcattatac Exon 10
cRHx1F agctctaagtacccgcggtctgtcc Exon 1
cRHx5R tggccagaacatccacaagaagag Exon 5
cRHx4F acgatacccagtttgtctgccatg Exon 4
cRHx10R tgaacaggccttgtttttcttggatgc Exon 10
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